ALISO VIEJO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced today that it intends to offer and sell, subject to market and other conditions, $40.0
